Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases
Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases
复制标题
DOI：
10.3109/08916934.2015.1104671
复制
发表时间：
2016-01
期刊：
影响因子：
3.5
通讯作者：
Zeping Zhou;Z. Qiao;Huiyuan Li;Na Luo;Xian Zhang;F. Xue;R. Yang
中科院分区：
文献类型：
--
作者：
Zeping Zhou;Z. Qiao;Huiyuan Li;Na Luo;Xian Zhang;F. Xue;R. Yang
本文比较了不同剂量静脉注射免疫球蛋白（IVIg）对免疫性血小板减少症（ITP）的疗效。将167例ITP患者（成人91例，儿童76例）按IVIg剂量分为A、B、C三组，每组167例。91例成人患者的治疗反应在三组IVIg剂量之间无显著差异（p = 0.459）。3组成人静脉注射有效率分别为A组97.1%、B组97.2%和C组100%。A组血小板升至30 × 109/L的平均时间为2.5天，B组为3.2天，C组为2.9天（p = 0.324）。IVIg的中位消耗量A组为0.83 g/kg，B组为1.22 g/kg，C组为1.64 g/kg（p < 0.01）。在儿童组中也显示了类似的结果。随访结果显示，A、B、C组的临床结局无显著性差异。总之，低剂量IVIg治疗与高剂量方案一样有效，而不会增加患者发展为慢性ITP疾病的风险，这表明ITP患者可以通过较低的常规剂量IVIg方案进行更经济有效的治疗。
Abstract This study compared the effects of different dosages of intravenous immunoglobulin (IVIg) against immune thrombocytopenia (ITP). A total of 167 patients, 91 adults and 76 children, with ITP, followed-up for three years in the case-control study, were divided into three subgroups according to the dosages of IVIg administered: group A (0.2 g/kg/day), group B (0.3 g/kg/day) and group C (0.4 g/kg/day). The therapeutic response in 91 adult patients did not differ significantly among the three groups of IVIg dosages (p = 0.459). The response rate of IVIg treatment in the three adult groups was 97.1% for group A, 97.2% for group B and 100% for group C. The mean time for raising platelets to 30 × 109/L in group A was 2.5 days, group B 3.2 days and group C 2.9 days (p = 0.324). The median IVIg consumption in group A was 0.83 g/kg, group B 1.22 g/kg and group C 1.64 g/kg (p < 0.01). Similar results were shown in the children groups. The follow-up results showed no significant difference of clinical outcome between groups A, B and C. In conclusion, low-dose IVIg treatment is shown to be as effective as high-dose regimen without increasing the risk of developing the patients into chronic ITP conditions, suggesting that ITP patients could be treated more cost-effectively by lower conventional dosage of IVIg regimen.